Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cell Rep Med ; 5(2): 101380, 2024 Feb 20.
Artigo em Inglês | MEDLINE | ID: mdl-38242120

RESUMO

Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.


Assuntos
Células Supressoras Mieloides , Neoplasias , Humanos , Neutrófilos , Células Supressoras Mieloides/metabolismo , Células Supressoras Mieloides/patologia , Receptores de Prostaglandina E Subtipo EP2/metabolismo , Fator Estimulador de Colônias de Granulócitos/farmacologia , Fator Estimulador de Colônias de Granulócitos/metabolismo , Neoplasias/patologia , Antígeno CD52/metabolismo , Família de Moléculas de Sinalização da Ativação Linfocitária/metabolismo
2.
Nuklearmedizin ; 59(5): 356-364, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32542618

RESUMO

AIM: The objective of this study was to assess the impact of implementing FDG-PET imaging in treatment algorithms for differentiated thyroid cancer with suspected recurrence. Primary end points were overall, event-free and disease-specific survival. Secondary end points were therapies, disease control and the sensitivity and specificity of PET imaging. METHODS: 194 patients with DTC treated at our center from 1996 to 2014 following thyroidectomy and routine 131I ablation with no remaining 131I uptake in whole-body scans but persisting or rising thyroglobulin values were enrolled in this retrospective analysis. Of these, 149 (76.8 %) received an 18F-FDG scan (PET group) whereas the remaining 45 patients (23.2 %) did not (non-PET group). Survival, disease-specific characteristics at inclusion, disease control and therapies were compared. RESULTS: Patients of the PET group generally showed characteristics associated with higher disease activity from inclusion onwards. This did not translate to statistically significant differences in survival. If PET imaging was performed following inclusion, patients received significantly less radioiodine treatments during the first nine months after inclusion (63.1 % of the PET-group vs 82.2 % of the non-PET group). Simultaneously, patients tended to receive more surgeries following PET imaging (27.5 % PET-group vs 13.3 % non-PET group). No significant differences regarding disease control were observed. CONCLUSION: The early use of FDG-PET imaging in cases of suspected recurrence or existence of dedifferentiated DTC can lead to changes in therapy management, specifically identifying patients unlikely to benefit from additional radioiodine therapy who would instead qualify for surgical therapy methods.


Assuntos
Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons , Tireoglobulina/metabolismo , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/metabolismo , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias da Glândula Tireoide/terapia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA